Dewpoint Therapeutics, Inc. is a Boston-based clinical-stage biotechnology company and the first founded to apply biomolecular condensate biology to drug discovery. Condensates are membraneless compartments that organize cellular chemistry, and Dewpoint's thesis is that many diseases arise from their dysregulation, opening targets previously considered undruggable. The company discovers small-molecule condensate modulators, or c-mods, using ERSAi, a proprietary AI-enabled discovery platform that codifies relationships between condensates, human disease, and chemistry. Its pipeline spans oncology, neurodegeneration, cardiopulmonary, and metabolic disease, with research sites in Boston and Dresden, Germany, and it has raised roughly $287 million across Series A, B, and C rounds.